Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment
Open Access
- 21 May 2019
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 72 (8) , 542-549
Abstract
Aims: Limited information is available regarding the precise differences in the tumour immune microenvironment (TIM) of patients with human papilloma virus (HPV)-associated and non-HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Here, we retrospectively reviewed 137 patients with OPSCC treated with a definitive treatment to identify molecular relationships in the TIM. Materials and methods: We used immunohistochemical analysis to assess p16 status, programmed death ligand 1 (PD-L1) level, and/or CD8 + tumour-infiltrating lymphocyte (TIL) density, followed by prognostic evaluation of these immune-related parameters. Results: Multivariate analyses demonstrated that PD-L1 level on immune cells but not on tumour cells or CD8 + TIL density was a significant predictive factor of disease-free survival (DFS) and overall survival (OS). Additionally, subgroup analyses demonstrated that patients positive for p16 and PD-L1 expression on immune cells had favourable DFS and OS, whereas patients negative for p16 and PD-L1 expression on immune cells showed worse DFS and OS. Conclusions: We demonstrated that PD-L1 expression on immune cells but not tumour cells might represent a useful prognostic biomarker in patients with OPSCC receiving a definitive treatment. We propose that a co-assessment of p16 and PD-L1 expression on immune cells would have greater prognostic potential compared with evaluation of each factor alone in patients with OPSCC.Keywords
This publication has 30 references indexed in Scilit:
- Classifying Cancers Based on T-cell Infiltration and PD-L1Cancer Research, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trialAnnals of Oncology, 2014
- PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck CancerCancer Research, 2013
- B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell CarcinomaHead and Neck Pathology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturationMedical Oncology, 2010
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+The Prostate, 2009